Chiasma (Chiasma) Cash, Cash Equivalents, Marketable Securities : $115.03 Mil (As of Mar. 2021)

View and export this data going back to 2015. Start your Free Trial

What is Chiasma Cash, Cash Equivalents, Marketable Securities?

Chiasma's quarterly cash, cash equivalents, marketable securities declined from Sep. 2020 ($156.76 Mil) to Dec. 2020 ($135.42 Mil) but then stayed the same from Dec. 2020 ($135.42 Mil) to Mar. 2021 ($115.03 Mil).

Chiasma's annual cash, cash equivalents, marketable securities increased from Dec. 2018 ($41.66 Mil) to Dec. 2019 ($92.38 Mil) and increased from Dec. 2019 ($92.38 Mil) to Dec. 2020 ($135.42 Mil).

Chiasma Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Chiasma's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiasma Cash, Cash Equivalents, Marketable Securities Chart

Chiasma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

92.98

66.94

41.66

92.38

135.42

Chiasma Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															79.26	67.09	156.76	135.42	115.03

Chiasma Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Chiasma (NAS:CHMA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Chiasma Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Chiasma's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiasma (Chiasma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiasma Inc (NAS:CHMA) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

140 Kendrick Street, Building C East, Needham, MA, USA, 02494

Website

https://www.chiasmapharma.com

Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.

Executives

Roni Mamluk	director	CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
David M Stack	director	THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Bard Geesaman	director	C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142
Todd Foley	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
John A Scarlett	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Scott Minick	director	C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139
Anand Varadan	officer: EVP, Chief Commerical Officer	C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Lee Giguere	officer: General Counsel	C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
William Ludlam	officer: See Remarks	C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
Drew Enamait	officer: VP, Fin & Admin, PAO	C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451
Mark J. Fitzpatrick	officer: President	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ansbert Gadicke	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116